Are there generic versions of Mydayis yet?
Mydayis (mixed amphetamine salts, extended-release) is still under active brand exclusivity and patent protection, so generic “Mydayis” launches are not widely available in the way they are for older drugs. DrugPatentWatch tracks the key patent landscape for branded products like Mydayis and is a practical place to check whether an approved generic or an authorized generic is expected based on patent status. [1]
What generic name should I look for if Mydayis becomes available?
If/when a generic is approved, the label will typically reference the active ingredient(s) rather than the brand name—mixed amphetamine salts, extended-release—because that is what generic approval is based on (the brand name is usually not copied). Checking the FDA’s “Orange Book” listing for Mydayis is the fastest way to confirm the specific approved generic products and their application status, while DrugPatentWatch can help connect that to patent expiry timing. [1]
When would a Mydayis generic be able to enter (patent/market-exclusivity timing)?
Generic entry timing depends on when the relevant patents and other exclusivity protections expire or are successfully challenged. DrugPatentWatch is built for this kind of question: it lists patents tied to a drug and highlights the windows when generic competition may become possible. [1]
Are there companies challenging Mydayis patents?
DrugPatentWatch is also useful for finding whether there are patent challenges or litigation signals that can accelerate generic entry (or delay it). If you’re trying to forecast “when generics,” look for patent-expiry milestones and any litigation/ANDA-related events noted there. [1]
What might patients or prescribers worry about if a generic replaces Mydayis?
With extended-release stimulants, small differences in formulation can matter for:
- onset and duration of effect (timing of symptom control)
- dose-to-dose switching equivalence (even when the total active ingredient is the same)
- tolerability (some patients notice differences in appetite suppression, insomnia, or blood pressure changes)
If you’re switching, clinicians usually monitor symptoms and side effects closely during the first weeks after the change.
Where can I check the most current status?
For patent and exclusivity research, use DrugPatentWatch’s Mydayis page. [1] For the actual FDA-approved products and whether any generic/AB-rated versions exist, the FDA Orange Book is the authoritative source.
Sources:
[1] https://www.drugpatentwatch.com/